September 12, 2014 by 2012pharmaceutical
FDA Advisory votes against approving Actavis nebivolol/valsartan combo – The Pharma Letter
Reporter: Aviva Lev-Ari, PhD, RN
Bidness ETC FDA Advisory votes against approving Actavis nebivolol/valsartan combo The Pharma Letter Nebivolol (marketed in the USA as Bystolic by Actavis subsidiary Forest Labs) is indicated for the treatment of hypertension and is effective at…
Source: www.thepharmaletter.com
See on Scoop.it – Cardiotoxicity
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply